Cetuximab, Irinotecan Evaluated in KRAS G13D-mutated mCRC

Share this content:
No statistically significant improvement in disease control at 6 months with either single-agent cetuximab or cetuximab plus irinotecan.
No statistically significant improvement in disease control at 6 months with either single-agent cetuximab or cetuximab plus irinotecan.

In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) harboring the exon 2 KRAS G13D mutation, there was no statistically significant improvement in disease control at 6 months with either single-agent cetuximab or cetuximab plus irinotecan, according to findings published in the Journal of Clinical Oncology.1

Although RAS mutations predict lack of response to epidermal growth factor receptor (EGFR) monoclonal antibody therapies like cetuximab, preclinical studies and retrospective clinical findings suggest that patients with the exon 2 KRAS G13D mutation may derive benefit from cetuximab therapy.

Therefore, researchers sought to evaluate cetuximab monotherapy and in combination with irinotecan in chemotherapy-refractory patients with mCRC who have this rare molecular subtype.

For the phase 2 ICECREAM trial, researchers enrolled 51 patients with KRAS G13D mutation-positive mCRC who had progressed within 6 months of irinotecan therapy. Participants were randomly assigned to receive cetuximab 400 mg/m2 as a loading dose, followed by 250 mg/m2 once weekly with or without irinotecan 180 mg/mg2 once every 2 weeks.

Results showed that the 6-month progression-free survival rate was 10% (95% CI, 2 - 26) with cetuximab monotherapy compared with 23% (95% CI, 9 - 40) for the combination (HR, 0.74; 95% CI, 0.42 - 1.32).

Researchers found that 0% of patients in the monotherapy arm and 9% of patients in the combination arm achieved a response. Stable disease was observed in 58% and 70%, respectively. The responses observed with the combination may represent true drug synergy or continued sensitivity to irinotecan. In addition, overall survival was similar between the 2 groups.

RELATED: Trastuzumab Plus Lapatinib Active in Refractory HER2+ Metastatic Colorectal Cancer

In terms of safety, toxicities were more frequently reported in the patients that received irinotecan. Quality of life was similar between the 2 treatment arms.

Reference

  1. Segelov E, Thavaneswaran S, Waring PM, et al. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study [published online ahead of print April 25, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.6843.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters